Statistics from Altmetric.com
Early initiation of treatment in Parkinson’s disease prevents patient-reported deteriorations, but what is gained?
The paper by Grosset et al1 (see p 465) in this issue describes self-reported health in a “real-life” cohort of dopa-naïve people with Parkinson’s disease (PD). Assessments using the Parkinson’s Disease Questionnaire (PDQ)-39 at initial consultation and for up to 18 months thereafter suggest stable self-reported health among patients who were started on dopaminergic treatment, whereas those who remained dopa-naïve deteriorated.
These observations add valuable fuel to the discussion on when to start dopaminergic treatment in PD.2,3 However, it remains to be determined whether initial benefits last in the long term, or …